Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL
Linus Wahnschaffe, Till Braun, Sanna Timonen, et al.
Cancers (2019) Vol. 11, Iss. 12, pp. 1833-1833
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

SOCS Proteins in Immunity, Inflammatory Diseases, and Immune-Related Cancer
Mohamed Luban Sobah, Clifford Liongue, Alister C. Ward
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 118
Genomic profiling for clinical decision making in lymphoid neoplasms
Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2193-2227
Open Access | Times Cited: 107
JAK: Not Just Another Kinase
Ruchi Agashe, Scott M. Lippman, Razelle Kurzrock
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 12, pp. 1757-1764
Open Access | Times Cited: 70
JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences
Nils Ott, Laura Faletti, Maximilian Heeg, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 6, pp. 1326-1359
Open Access | Times Cited: 43
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
Alexandra Schrader, Giuliano Crispatzu, Sebastian Oberbeck, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 91
Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
Kalpana K. Bhanumathy, Balagopal Amrutha, Frederick S. Vizeacoumar, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 184-184
Open Access | Times Cited: 59
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody
Till Braun, Michael Rade, Maximilian Merz, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Structural and functional consequences of the STAT5BN642H driver mutation
Elvin D. de Araujo, Fettah Erdogan, Heidi A. Neubauer, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 67
Advances and Perspectives in the Treatment of T-PLL
Till Braun, Jana von Jan, Linus Wahnschaffe, et al.
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 2, pp. 113-124
Open Access | Times Cited: 42
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
Krimo Toutah, Nabanita Nawar, Sanna Timonen, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 8486-8509
Open Access | Times Cited: 34
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia
Dipabarna Bhattacharya, Antonella Teramo, Vanessa Rebecca Gasparini, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 2
Open Access | Times Cited: 26
Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer
Al‐Hassan M. Mustafa, Oliver H. Krämer
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 35-61
Closed Access | Times Cited: 22
Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer
Fahim Anwar Rizwi, Md. Abubakar, Eswara Rao Puppala, et al.
Journal of Environmental Pathology Toxicology and Oncology (2023) Vol. 42, Iss. 4, pp. 15-29
Closed Access | Times Cited: 13
Mature T-Cell Neoplasms and Natural Killer-Cell Malignancies
Anne Tierens
Cambridge University Press eBooks (2025), pp. 141-163
Closed Access
T-cell prolymphocytic leukemia, a case report and review of the literature
Luis Manuel GONZáLEZ-RODRíGUEZ, Luis Miguel Juárez‐Salcedo, Javier Loscertales, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2025) Vol. 33, Iss. 3, pp. 505-517
Closed Access
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia
Charles Herbaux, Christoph Kornauth, Stéphanie Poulain, et al.
Blood (2021) Vol. 137, Iss. 25, pp. 3495-3506
Open Access | Times Cited: 28
Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses
Jana von Jan, Sanna Timonen, Till Braun, et al.
Blood (2024) Vol. 144, Iss. 15, pp. 1595-1610
Closed Access | Times Cited: 4
The Many Faces of Philadelphia: A Mature T-Cell Lymphoma with Variant Philadelphia-Translocation and Duplication of the Philadelphia Chromosome
Livia Vida, Bálint Horváth, Miklós Egyed, et al.
Hematology Reports (2025) Vol. 17, Iss. 1, pp. 1-1
Open Access
Spotlight on amino acid changing mutations in the JAK-STAT pathway: from disease-specific mutation to general mutation databases
Markus Hoffmann, Lothar Hennighausen
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Exome-wide association study reveals 7 functional variants associated with ex-vivo drug response in acute myeloid leukemia patients
Anil K Giri, Jake Lin, Konstantinos Kyriakidis, et al.
BMC Medical Genomics (2025) Vol. 18, Iss. 1
Open Access
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia
Annika Dechow, Sanna Timonen, Aleksandr Ianevski, et al.
Leukemia (2025)
Open Access
T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases
Zhihong Hu, L. Jeffrey Medeiros, Mina L. Xu, et al.
American Journal of Clinical Pathology (2023) Vol. 159, Iss. 4, pp. 325-336
Closed Access | Times Cited: 10
Computer-Aided Drug Design of Novel Derivatives of 2-Amino-7,9-dihydro-8H-purin-8-one as Potent Pan-Janus JAK3 Inhibitors
Abdelmoujoud Faris, Ibrahim M. Ibrahim, Omkulthom Al Kamaly, et al.
Molecules (2023) Vol. 28, Iss. 15, pp. 5914-5914
Open Access | Times Cited: 8
Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies
Allison R. Greenplate, Kai Wang, Rati Tripathi, et al.
JCO Precision Oncology (2018), Iss. 2, pp. 1-16
Open Access | Times Cited: 27
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research
Hemant S. Murthy, Kwang Woo Ahn, Noel Estrada‐Merly, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 4, pp. 187.e1-187.e10
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top